Evidence map›Paper›PMID 32249345›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2020

Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.

Orazio Caffo, Viviana Frantellizzi, Marcello Tucci, Luca Galli, Fabio Monari, Sergio Baldari, Cristina Masini, Roberto Bortolus, Gaetano Facchini, Pierpaolo Alongi and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Orazio CaffoDepartment of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100, Trento, Italy. orazio.caffo@apss.tn.it.
Viviana FrantellizziDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy.
Marcello TucciDepartment of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy.
Luca GalliDepartment of Medical Oncology, AOU Pisana, Pisa, Italy.
Fabio MonariDepartment of Radiotherapy, S. Orsola Malpighi Hospital, Bologna, Italy.
Sergio BaldariDepartment of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
Cristina MasiniDepartment of Medical Oncology, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy.
Roberto BortolusDepartment of Radiation Oncology, NCI-IRCCS of Aviano, Aviano, Italy.
Gaetano FacchiniDepartmental Unit of Experimental Uro-Andrological Clinical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
Pierpaolo AlongiNuclear Medicine Unit, Fondazione Istituto G.Giglio, Cefalù, Italy.
Stefania AgostiniDepartment of Nuclear Medicine, Santa Chiara Hospital, Trento, Italy.
Clizia ZichiDepartment of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy.
Elisa BiascoDepartment of Medical Oncology, AOU Pisana, Pisa, Italy.
Stefano FantiDepartment of Nuclear Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
Salvatore PignataDepartment of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
Angelina FiliceDepartment of Nuclear Medicine, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy.
Eugenio BorsattiDepartment of Nuclear Medicine, NCI of Aviano, Aviano, Italy.
Sabrina RossettiDepartmental Unit of Experimental Uro-Andrological Clinical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
Massimiliano SpadaDepartment of Medical Oncology, Fondazione Istituto G.Giglio, Cefalù, Italy.
Enrico CortesiDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy.
Giuseppe De VincentisDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy.
Sapienza University of Rome · ITFondazione Istituto G. Giglio di Cefalù · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITOspedale San Luigi Gonzaga · ITOspedale Santa Chiara · ITOspedale Santa Maria · ITPoliclinico S.Orsola-Malpighi · ITUniversity of Messina · ITCentro di Riferimento Oncologico · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl MATERIALS: We retrospectively reviewed the records of mCRPC patients who received [223Ra]RaCl

resultsWe reviewed data of a consecutive series of 94 mCRPC patients. Most of the patients (85.1%) received [223Ra]RaCl

conclusionThe findings of this study show that the treatment with [223Ra]RaCl

Indexed as

Bone NeoplasmsProstatic Neoplasms, Castration-ResistantRadiumAbiraterone AcetateHumansMaleRetrospective StudiesTreatment OutcomeAbiraterone AcetateRadiumRadium-223AbirateroneFracturative riskRadium 223SafetySequencing

Identifiers

PMID32249345
OpenAlexW3014540548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.